The toll revenue growth was supported by healthy traffic growth, the addition of new TOT and BOT assets and tariff revisions at the beginning of the year. Amitabh Murarka, Deputy CEO of IRB Infrastructure Developers, said the performance reflected the strength of the company’s expanded asset portfolio and sustained economic activity across its corridors.
“Looking ahead, we will continue to follow a disciplined capital allocation strategy, focusing on acquiring high-quality assets and creating sustainable, long-term value for our stakeholders,” Murarka said.
Separately, IRB InvIT’s toll revenue increased 12.2% year-on-year to ₹158.1 crore in July, compared with ₹141 crore in the year-ago period, according to its July business update.
IRB Infra Q1 results
For the June quarter, IRB Infrastructure Developers reported a 51.2% year-on-year increase in consolidated net profit to ₹306.3 crore, from ₹202.5 crore a year earlier, driven by higher toll collections.
Revenue increased 1.8% to ₹2,137.3 crore from ₹2,098.9 crore a year earlier. EBITDA rose 21.1% to ₹1,152.4 crore from ₹951.9 crore, while the EBITDA margin stood at 53.9%, compared with 55.4% in the corresponding quarter last year.
Profit before tax rose to ₹416.6 crore from ₹286.4 crore a year ago, while total income was marginally higher at ₹2,172.7 crore compared with ₹2,164.6 crore. Finance costs declined to ₹438 crore from ₹462 crore in the year-ago period.
The company’s toll revenue increased 14% year-on-year to ₹733 crore from ₹646 crore, supported by the commissioning of the Ganga Expressway (Meerut-Budaun Group 1 BOT) and the commencement of tolling on TOT-18 (Chandikhole-Bhadrak NH-16) from April 1, 2026.
Chairman and Managing Director Virendra D Mhaiskar said the company was navigating global economic challenges on the back of its ₹94,000 crore asset portfolio and growing toll revenues, adding that its B.E.S.T. strategy remained on track.
The company is targeting an asset base of ₹1.4 lakh crore by 2030, supported by India’s infrastructure push and public-private partnership opportunities.
Also Read: Gland Pharma Q1 net profit jumps 47% on strong CDMO, B2B performance; revenue up 20%
